1. Introduction
===============

The innate immune system plays a central role in the detection of invading viral pathogens, and responds by activating inflammatory and antiviral defence mechanisms to combat the viral agents. To evade these defence machanisms, the influenza viruses are known to circumvent the potent antiviral interferon action by inhibiting the interferon regulatory factor 3 (IRF-3), and the general interferon signaling pathway [@bib1]. The viruses achieve this in part through their double stranded RNA (ds RNA) binding protein called non-structural protein-1 (NS-1) [@bib1]. By doing so, influenza viruses can replicate unabated in the host\'s respiratory tract.

During influenza viral replication, single stranded (ss RNA) and ds RNA are intermediate molecules which are recognized by the toll-like receptors (TLRs) which are expressed by cells of the innate immunity including dendritic cells, natural killer cells and macrophages [@bib2] as well as on respiratory epithelium and elsewhere. Toll-like receptors are transmembrane signaling proteins which are designed to specifically recognize various proteins, carbohydrates, lipids and nucleic acids of invading microorganisms. When activated, they trigger immune and inflammatory responses to respond to these infectious agents.

There are four known toll-like receptors which are found in mammalians cells and which recognize nucleic acids. These are TLR-3, TLR-7, TLR-8 and TLR-9 and these are found in the endosomal membranes [@bib2]. Since these nucleic acid-recognizing TLRs regulate the induction of type I interferon and other antiviral gene functions, they are rationale targets for antiviral drug development. Previous study had demonstrated that TLR-3 contributes to the immune response of respiratory epithelial cells to influenza and ds RNA [@bib3]. The molecular mechanism of this immune enhancement is generally believed to be mediated through mitogen-activated protein kinases, phosphatidylinositol 3-kinase/Akt signaling and the TLR-3 associated adaptor molecule TRIF [@bib3].

This paper outlines the antiviral activity of two TLR agonists and examines their applications in inducing protective antiviral immunity against influenza viruses, including seasonal and avian strains. Poly ICLC is a synthetic ds RNA condensed with poly-[l]{.smallcaps}-lysine and carboxymethylcellulose, and is a known TLR-3 agonists [@bib4]. The X-ray crystal structure of the poly IC:TLR-3 receptor signaling complex has been determined [@bib4]. Since TLR-3 activation by ds RNA results in induction of type I interferons, it follows that Poly ICLC, when delivered in liposomes to the endosomal membrane location, may strengthen the host antiviral defence against influenza virus by priming the interferon levels and, therefore, reversing the interferon knockdown by the viruses. In addition, oligonucleotides containing unmethylated CpG motifs, a TLR-9 agonist [@bib5], are evaluated as stand alone immunomodulating antiviral agents.

2. Materials and methods {#sec1}
========================

Poly ICLC, and oligonucleotides containing unmethylated CpG motifs used in this study were supplied by Oncovir Inc. (Washington, DC) and Oligos Etc Inc. (Wilsonville, OR), respectively. The method of preparation and lipid compositions of liposome-encapsulated poly ICLC have been previously described [@bib6].

2.1. RT-PCR
-----------

TLR-3 primers were procured from Applied Biosystems (ABI, Streetsville, ON). Mice were pre-treated with two intranasal doses of Poly ICLC, LE Poly ICLC (1 mg/kg body weight), sham liposomes or PBS given at 48 h apart. At 4, 24, 48 and 72 h post-drug treatment, mice were euthanized by cervical dislocation, and the lungs were aseptically removed and homogenized in Trizol. Total RNA was extracted from lung tissues by Trizol method (Invitrogen). One μg of RNA was used for DNase I (Fermentas) digestion before doing RT (reverse transcription) to make 1st strand cDNA. RT was performed using high capacity cDNA RT kit with random primers (ABI). Thermal profile for the RT step was as follows: 25 °C for 10 min (hold); 37 °C for 120 min (hold); 85 °C for 3 s (hold). Real-time PCR was performed using TaqMan probe-based detection (ABI) that was run on an ABI Fast 7500 System. TaqMan Gene Expression assay (ABI) consists of two unlabelled PCR primers and a FAM dye labelled TaqMan MGB (minor groove binder) probe. The PCR step was as follows: 95 °C for 20 s for enzyme activation, 40 cycles of denaturation at 95 °C for 3 s, annealing and extension at 60 °C for 30 s. β-Actin was used as an internal control to normalize the expression of target genes. Comparative Ct method for relative quantitation was used to calculate fold changes. Serial dilutions of different inputs of target and reference genes were performed to verify that efficiencies of target and reference are approximately equal (data not shown). Data analysis was performed using 7500 software v2.0 (ABI).

2.2. Pre-treatment study
------------------------

Poly ICLC and CpG oligonucleotides (CpG ODN), whether unencapsulated or encapsulated in liposomes were administered intranasally into 6--7-week-old (20 g body weight) Balb/c female mice. For the prophylaxis of influenza virus infection, groups of mice (8--10 animals per group) were given two doses of free or liposomal poly ICLC (1 mg/kg body weight) 48 h apart by the intranasal route. The volume of the inoculum used was 50 μl. At various days post-drug treatment, the mice were intranasally challenged with either 10 LD~50~ of influenza A/PR/8/34, or with 1-10 LD~50~ of influenza A/H5N1/chicken/Henan viruses. The animals were then monitored daily for symptoms of infection, body weights and survival. At day 14 post-infection, the number of mice which survived the virus infection in each group was recorded.

2.3. Statistical analysis
-------------------------

The survival patterns of the control and treated mice were graphed using the Log-rank test (GraphPad Prism version 4.01, San Diego, CA). The survival of the various test groups were compared to the control groups using the Log-rank test. Differences were considered significant at *p*  \< 0.05.

3. Results and discussion
=========================

3.1. Effect of Poly ICLC and LE Poly ICLC on TLR-3 mRNA expression in lungs
---------------------------------------------------------------------------

The effect of poly ICLC and LE Poly ICLC on the TLR-3 expression in the lungs of mice intranasally pre-treated with these drugs were determined by RT-PCR ([Fig. 1](#fig1){ref-type="fig"} ). Both Poly ICLC and LE Poly ICLC were found to up-regulate TLR-3 mRNA expression in the lung tissues ([Fig. 1](#fig1){ref-type="fig"}). Increased TLR-3 expression was detected as early as 4 h post-drug administration, and was still pronounced at 72 h post-drug administration. In contrast, sham liposomes (empty liposomes without poly ICLC) did not have any effect on TLR-3 expressions in the lungs. The magnitude of TLR-3 up-regulation was slightly higher in the Poly ICLC group for the 4, 24 and 72 h time points compared to the LE Poly ICLC, whereas LE Poly ICLC TLR-3 upregulation was higher compared to the Poly ICLC for the 48 h. The differences between Poly ICLC and LE poly ICLC on TLR-3 expression were not significant statistically. Similar increases in TLR-3 expression were also observed in the Poly ICLC and LE Poly ICLC groups in the spleens of mice but the increases were lower in magnitude and shorter in duration compared to the levels obtained in the lungs (data not shown).Fig. 1TLR-3 mRNA expression in the lungs of mice which received two intranasal administered doses of Poly ICLC, LE Poly ICLC (1 mg/kg body weight), sham liposomes and PBS were analyzed using qRT-PCR as described in Section [2](#sec1){ref-type="sec"}. Results were normalized to β-actin as endogenous control, and are shown as fold increases relative to the PBS control group. Error bars represent standard error of the mean.

3.2. The antiviral efficacy of Poly ICLC and LE Poly ICLC (TLR-3 agonists) against seasonal and avian strains of influenza A viruses
------------------------------------------------------------------------------------------------------------------------------------

Using established lethal influenza infection murine models previously described [@bib6], the protective activity of poly ICLC and LE poly ICLC against the various influenza A strains were determined by assessing the survival rates at day 14 post-infection with 10 LD~50~ dose of the influenza viruses ([Table 1](#tbl1){ref-type="table"} ). The results summarized show that both Poly ICLC and LE Poly ICLC were highly effective in the protection of mice against both seasonal and avian influenza viruses ([Table 1](#tbl1){ref-type="table"}). Pre-treatment of mice with Poly ICLC or LE poly ICLC were found to be more efficacious than pre-treatment with exogenously administered IFN-α or IFN-γ against influenza A/PR/8/34. The data from these studies suggest that the prophylactic protection provided by Poly ICLC and LE poly ICLC is broad-spectrum, effective and protects against H1N1, H3N2 and H5N1 strains.Table 1Prophylactic activity of Poly ICLC, LE Poly ICLC and IFNs against various strains of influenza A viruses in mice.GroupInfluenza strainLD50% Survival vs. controlPoly ICLCA/PR/8/34 (H1N1)10100% vs. 0%A/Aichi/2 (H3N2)10100% vs. 0%Henan/2005 (H5N1)10ND  LE Poly ICLCA/PR/8/34 (H1N1)10100% vs. 0%A/Aichi/2 (H3N2)10100% vs. 0%Henan/2005 (H5N1)1100% vs. 50%Henan/1067% vs. 0%  IFN-αA/PR/8/341050% vs. 0%IFN-γA/PR/8/341050% vs. 0%

The duration of protection provided by Poly ICLC and LE poly ICLC was previously reported [@bib6]. LE Poly ICLC provided 100% protection against 10 LD~50~ influenza A/PR/8/34 when pre-treatment was given for up to 21 days prior to virus challenge. In comparison, pre-treatment with Poly ICLC was 100% protective when given up to 7 days prior to virus challenge, and it provided 80% protection when given at 14 days prior to virus challenge [@bib6]. The longer duration of LE Poly ICLC compared to Poly ICLC was assumed to be attributable to liposome delivery and gradual release of the Poly ICLC from the liposomes. This remains to be confirmed.

3.3. The antiviral activity of CpG oligos (TLR-9 agonist) against influenza A/PR/8/34 in mice
---------------------------------------------------------------------------------------------

In a study evaluating the efficacy of CpG ODN against influenza, mice were given 5 μg of a CpG ODN 4 days prior to infection with a lethal dose of influenza A/PR/8/34 (H1N1) ([Fig. 2](#fig2){ref-type="fig"} ). Using this model, mice pre-treated with CpG ODN and liposome-encapsulated CpG ODN were completely protected (100% survival rates at day 14 post-infection) against the otherwise lethal virus challenge. Studies will be carried out to determine whether the incorporation of CpG ODNs in liposomes would confer a longer window of protection compared to unencapsulated CpG ODNs.Fig. 2Efficacy of CpG ODN prophylaxis against influenza viral challenge. Mice were intranasally given 5 μg (0.25 mg/kg body weight) of free or liposome-encapsulated CpG ODN (Lip-CPG ODN) 4 days prior to infection with influenza A/PR/8/34. Liposomes were composed of dimyristoltrimethylammonium propane/cholesterol/dioleylphosphatidyl choline (molar ratio of 25:50:25). Mice (*n* = 5) were monitored daily for appearance, weight and survival. Graph shows the percentage of mice surviving 14 days after challenge.

4. Conclusion
=============

The results presented affirm the antiviral role of nucleic acid-based TLR agonists such as Poly ICLC and CpG ODNs for the broad-spectrum protection against various seasonal and avian influenza A viruses. The activation of the TLR signaling pathway results in the stimulation of both innate and adaptive immune responses and may be partially responsible for the antiviral state against influenza infections. Influenza viruses are highly effective and adaptable infectious agents which can overcome antiviral therapy by developing drug resistance, and by overcoming the host\'s immune defence mechanisms. Conventional anti-influenza drugs target the virus structure, and they are susceptible to the emergence of drug resistance. Animal studies suggest that activation of TLR signaling pathway by TLR agonists provides protection not only against influenza virus infections, but also respiratory syncytial virus [@bib7], SARS-CoV [@bib8], and hepatitis B [@bib9], among others. The activation of the toll-like receptor signaling pathway may represent an effective broad-spectrum strategy against these viruses. This approach targets the cells of the innate immune system and hence, is less likely to result in drug resistance. In addition, it provides an effective means to enhance and/or restore interferon production during viral replication. In summary, TLR agonists may represent an affective and broad-spectrum antiviral strategy to combat influenza viruses which are unpredictable and ever changing.
